Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A type of renal carcinoma affecting mostly young African-Americans. It is located in the medulla of the kidney, and follows an aggressive clinical course. Most reported cases have shown metastatic disease at the time of diagnosis.
Biomarker and diagnostic research for kidney medullary carcinoma has been reported in the published literature.
11 clinical trials registered, 2 recruiting. Interventions under study include drug therapy, procedural interventions, biologic therapy, and other interventions. Pipeline includes 8 PHASE2, 2 PHASE1. Research is primarily sponsored by academic and government institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT06302569](https://clinicaltrials.gov/study/NCT06302569) |
Data assembled from 4 of 12 sources · Last updated Sep 20, 2026, 4:05 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma |
PHASE2 |
Giuseppe Procopio |
RECRUITING |
[NCT03866382](https://clinicaltrials.gov/study/NCT03866382) | Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors | PHASE2 | National Cancer Institute (NCI) | RECRUITING |
83 publications have been identified in PubMed for kidney medullary carcinoma. Research spans Review / Meta-Analysis (29%), Case Report / Case Series (28%), and Clinical Trial Publication (13%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 23 | 29% |
Patient case studies | 22 | 28% |
Clinical study results | 10 | 13% |
Laboratory research | 8 | 10% |
Disease patterns and progression | 7 | 9% |
Testing and diagnosis research | 6 | 8% |
Other research | 1 | 1% |
New treatment approaches | 1 | 1% |
Toma MI (2026). [PMID: 41344358](https://pubmed.ncbi.nlm.nih.gov/41344358/). *Aktuelle Urol*. [Review / Meta-Analysis]
Gounder M (2026). [PMID: 41882006](https://pubmed.ncbi.nlm.nih.gov/41882006/). *Nat Commun*. [Clinical Trial Publication]
Kunutsor SK (2026). [PMID: 41351656](https://pubmed.ncbi.nlm.nih.gov/41351656/). *Drugs*. [Review / Meta-Analysis]
Worku D (2026). [PMID: 41959950](https://pubmed.ncbi.nlm.nih.gov/41959950/). *Cureus*. [Case Report / Case Series]
Sang F (2026). [PMID: 41883969](https://pubmed.ncbi.nlm.nih.gov/41883969/). *Front Oncol*. [Case Report / Case Series]
Luo W (2026). [PMID: 41666682](https://pubmed.ncbi.nlm.nih.gov/41666682/). *Ann Diagn Pathol*. [Review / Meta-Analysis]
Weston W (2026). [PMID: 41954690](https://pubmed.ncbi.nlm.nih.gov/41954690/). *Int Urol Nephrol*. [Review / Meta-Analysis]
Rametta A (2026). [PMID: 41517842](https://pubmed.ncbi.nlm.nih.gov/41517842/). *Expert Rev Clin Pharmacol*. [Review / Meta-Analysis]
Ortiz MV (2026). [PMID: 41478859](https://pubmed.ncbi.nlm.nih.gov/41478859/). *Nat Rev Urol*. [Review / Meta-Analysis]
Huo B (2026). [PMID: 42016441](https://pubmed.ncbi.nlm.nih.gov/42016441/). *Kidney Med*. [Case Report / Case Series]
AI-curated news mentioning kidney medullary carcinoma
Updated Apr 14, 2026
Research highlights the challenges in treating renal medullary carcinoma (RMC), particularly in young athletes with sickle cell trait. Loss of the SMARCB1 gene renders standard anti-VEGF therapies and immune checkpoint inhibitors ineffective, prompting a call for clinical trials to explore alternative immunotherapy strategies.